-
Home
- Products & Services
- Explore Product Lookup
- Solutions
- Cardiometabolic
-
Infectious Disease
- C. difficile
- Cryptosporidiosis
- Dengue Fever
- E. coli
- Enterics
- Epstein Barr Virus (EBV)
- GI Parasites
- Hepatitis
- Hepatitis
- Herpes Simplex Virus
- HIV
- Intestinal Inflammation
- Legionnaire's Disease
- Leptospira
- Influenza (Flu)
- Malaria
- Mononucleosis
- MRSA
- Pneumonia
- Ross River/Barmah Forest
- RSV
- Rubella
- S. aureus
- Strep A pharyngitis
- Streptococcus pneumoniae
- Syphilis
- C-reactive Protein Diagnostic Tests
- Tuberculosis
- Other Infectious Disease
- Toxicology
- Toxicology Products & Services
- Other
-
Browse by Brand
- Afinion
- Alere Actim
- BinaxNOW
- Alere Cholestech LDX
- Alere Determine
- Alere hCG
- Alere™ i
- Alere NMP22
- Alere PBP2a
- Alere Pima CD4
- Alere q
- Alere TestPack
- Alere Toxicology
- AegisPOC
- Clearview
- Alere Determine
- NHS Health Checks
- i-STAT System
- iCup
- ID NOW™ (formerly Alere™ i)
- NycoCard
- RALS®
- Standard Diagnostics
- TECHLAB
- Wampole
- Additional Brands
- NHS Health Checks
- Patient Learning Series
- For Patients
Clostridium difficile
The C. difficile bacterium is responsible for the most common form of hospital-acquired diarrhea and antibiotic-associated colitis. It is highly infectious and a significant danger to the health of immunocompromised or elderly patients. The infection can be life-threatening when not caught in time to allow for appropriate therapy. In U.S. hospitals alone, current annual spending is estimated at $40 million in testing aimed at diagnosing C. difficile to provide appropriate therapy and control the spread of the disease.